1. Home
  2. ESPR vs TSHA Comparison

ESPR vs TSHA Comparison

Compare ESPR & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.86

Market Cap

898.5M

Sector

Health Care

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$5.81

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESPR
TSHA
Founded
2008
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
898.5M
1.2B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
ESPR
TSHA
Price
$3.86
$5.81
Analyst Decision
Buy
Strong Buy
Analyst Count
7
9
Target Price
$6.86
$10.22
AVG Volume (30 Days)
6.5M
3.4M
Earning Date
11-06-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$303,802,000.00
$6,310,000.00
Revenue This Year
$25.45
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.83
N/A
52 Week Low
$0.69
$1.05
52 Week High
$4.13
$5.95

Technical Indicators

Market Signals
Indicator
ESPR
TSHA
Relative Strength Index (RSI) 61.15 67.47
Support Level $3.72 $5.22
Resistance Level $4.00 $5.54
Average True Range (ATR) 0.26 0.32
MACD 0.01 0.15
Stochastic Oscillator 75.24 92.43

Price Performance

Historical Comparison
ESPR
TSHA

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: